Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
PerimenopauseMenstrual Cramps
Interventions
DRUG

Oral Micronized Progesterone

The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.

DRUG

Placebo

pill with no effect

Trial Locations (1)

V5Z 1M9

Participation from home or in-person at University of British Columbia/Centre for Menstrual Cycle and Ovulation Research (CeMCOR)/Vancouver Coastal Health Research Institute, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER

NCT02779582 - Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow | Biotech Hunter | Biotech Hunter